NASDAQ$UTHR
United Therapeutics Corp · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
United Therapeutics Corp reported Q2 2025 net income of $309.5 million on total revenues of $798.6 million.
The company achieved 12% year-over-year revenue growth driven primarily by Tyvaso DPI and Nebulized Tyvaso sales. Operating income reached $364.5 million with net income per diluted share of $6.41, reflecting strong performance across treprostinil-based therapies.
- Total revenues grew 12% to $798.6 million year-over-year
- Tyvaso DPI revenues increased 22% to $315.2 million
- Net income rose 11% to $309.5 million with diluted EPS of $6.41
- US revenues accounted for 95% of total at $759.8 million
Headline financials
Revenue & EPS history
United Therapeutics · Revenue · Quarterly
$799M
Revenue by segment
United Therapeutics · $799M total across 7 segments · Q2 2025
- Tyvaso DPI$315M—39.5%
- Nebulized Tyvaso$154M—19.3%
- Remodulin$135M—16.9%
- Orenitram$124M—15.5%
- Unituxin$58.4M—7.3%
- Adcirca$6.5M—0.8%
- Other$5.5M—0.7%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+0.6%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+1.1%
Avg return
30 days after
57%
39 / 68 earnings
Positive
+16.2%
Q3 2022
Best reaction
-13.0%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +4.3% | -0.4% | -4.0% | |
| Q4 2025 | +13.1% | +8.5% | +10.4% | |
| Q3 2025 | +9.7% | +5.6% | +17.0% | |
| Q1 2025 | +0.8% | -0.7% | +6.0% | |
| Q4 2024 | -10.8% | -13.3% | -14.1% | |
| Q3 2024 | +6.0% | +6.8% | +5.0% | |
| Q2 2024 | -2.9% | -3.5% | +7.7% | |
| Q1 2024 | +10.2% | +11.2% | +17.4% | |
| Q4 2023 | +1.6% | +4.4% | +11.1% | |
| Q3 2023 | +2.4% | +2.4% | +8.0% | |
| Q2 2023 | -3.4% | -1.0% | -5.0% | |
| Q1 2023 | -5.7% | -8.0% | -5.1% | |
| Q4 2022 | -2.7% | -3.3% | -13.8% | |
| Q3 2022 | +16.2% | +16.8% | +22.0% | |
| Q2 2022 | -1.5% | -2.7% | -0.8% | |
| Q1 2022 | +4.1% | -0.6% | +27.2% | |
| Q4 2021 | -13.0% | -14.0% | -9.5% | |
| Q3 2021 | +4.8% | +5.1% | -3.2% | |
| Q2 2021 | +13.7% | +15.0% | +16.7% | |
| Q1 2021 | -1.7% | -2.8% | -9.9% | |
| Q4 2020 | -2.1% | -0.6% | -0.7% | |
| Q3 2020 | +5.6% | +8.6% | +9.8% | |
| Q2 2020 | +0.3% | +2.9% | -6.3% | |
| Q1 2020 | -0.2% | +2.0% | +7.5% | |
| Q4 2019 | -10.7% | -8.0% | -19.1% | |
| Q3 2019 | +3.3% | +3.6% | +6.1% | |
| Q2 2019 | +4.5% | -0.5% | +3.8% | |
| Q1 2019 | -1.3% | -1.9% | -18.1% | |
| Q4 2018 | +3.6% | -1.5% | -3.8% | |
| Q3 2018 | -6.2% | -6.2% | -3.7% | |
| Q2 2018 | +0.3% | +0.7% | +0.1% | |
| Q1 2018 | -8.3% | -8.3% | -4.2% | |
| Q4 2017 | -12.9% | -14.1% | -20.4% | |
| Q3 2017 | +0.2% | +0.8% | +5.1% | |
| Q2 2017 | -2.3% | -2.6% | -2.2% | |
| Q1 2017 | -1.0% | +1.0% | -2.2% | |
| Q4 2016 | -12.2% | -9.2% | -16.6% | |
| Q3 2016 | +4.5% | +6.0% | +19.0% | |
| Q2 2016 | +6.9% | +11.2% | +7.6% | |
| Q1 2016 | -10.6% | — | — | |
| Q4 2015 | -4.2% | — | — | |
| Q3 2015 | +8.8% | — | — | |
| Q2 2015 | +0.8% | — | — | |
| Q1 2015 | -4.4% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | +2.7% | — | — | |
| Q1 2014 | +12.4% | — | — | |
| Q4 2013 | -4.1% | — | — | |
| Q3 2013 | +3.8% | — | — | |
| Q2 2013 | +2.7% | — | — | |
| Q1 2013 | -1.6% | — | — | |
| Q4 2012 | +2.7% | — | — | |
| Q3 2012 | +2.9% | — | — | |
| Q2 2012 | +8.3% | — | — | |
| Q1 2012 | +0.8% | — | — | |
| Q4 2011 | -0.9% | — | — | |
| Q3 2011 | +8.0% | — | — | |
| Q2 2011 | +5.0% | — | — | |
| Q1 2010 | -5.3% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q4 2008 | +1.8% | — | — | |
| Q4 2010 | +1.8% | — | — | |
| Q3 2009 | +8.0% | — | — | |
| Q3 2010 | +8.0% | — | — | |
| Q4 2009 | -8.2% | — | — | |
| Q2 2010 | -8.2% | — | — | |
| Q2 2009 | -8.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro